Richard K Zimmerman
Overview
Explore the profile of Richard K Zimmerman including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
265
Citations
4648
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Williams K, Krauland M, Nowalk M, Nowalk M, Harrison L, Williams J, et al.
J Infect
. 2025 Feb;
90(3):106443.
PMID: 39952478
Objectives: Availability of caregiver-administered nasal spray live attenuated influenza vaccine (LAIV) raises the potential for increased influenza vaccine uptake. Direct and indirect benefits (decreased influenza cases and hospitalizations) of increased...
2.
Huang P, Nowalk M, Zimmerman R, Olson S, Talbot H, Zhu Y, et al.
Hum Vaccin Immunother
. 2025 Jan;
21(1):2457205.
PMID: 39875316
Influenza causes 100,000-710,000 hospitalizations annually in the U.S. Patients with liver disease are at higher risk of severe outcomes following influenza infection. This study evaluated influenza vaccine effectiveness (VE) against...
3.
Chung J, Price A, Zimmerman R, Moehling Geffel K, House S, Curley T, et al.
Clin Infect Dis
. 2025 Jan;
PMID: 39761230
Background: The 2023-24 U.S. influenza season was characterized by a predominance of A(H1N1)pdm09 virus circulation with co-circulation of A(H3N2) and B/Victoria viruses. We estimated vaccine effectiveness (VE) in the United...
4.
Hughes Kramer K, Zimmerman R, Haggerty C, Balasubramani G, Nowalk M, Martin E, et al.
Hum Vaccin Immunother
. 2024 Dec;
20(1):2354013.
PMID: 39693194
While the number of immunocompromised (IC) individuals continues to rise, the existing literature on influenza vaccine effectiveness (VE) in IC populations is limited. Understanding the vaccine effectiveness (VE) of the...
5.
Smith K, Wateska A, Nowalk M, Lin C, Harrison L, Schaffner W, et al.
Am J Prev Med
. 2024 Nov;
68(3):518-526.
PMID: 39615769
Introduction: The potential impact of an in-development 24-valent pneumococcal conjugate vaccine compared with that of currently recommended vaccines in older adults is unclear. Similar to most currently available pneumococcal conjugate...
6.
Chung J, Price A, Zimmerman R, Moehling Geffel K, House S, Curley T, et al.
medRxiv
. 2024 Nov;
PMID: 39574872
Background: The 2023-24 U.S. influenza season was characterized by a predominance of A(H1N1)pdm09 virus circulation with co-circulation of A(H3N2) and B/Victoria viruses. We estimated vaccine effectiveness (VE) in the United...
7.
Williams K, Krauland M, Harrison L, Williams J, Roberts M, Zimmerman R
Am J Public Health
. 2024 Nov;
115(2):209-216.
PMID: 39541556
To estimate the effect of influenza vaccination disparities. We compared symptomatic influenza cases between Black and White races in 2 scenarios: (1) race- and age-specific vaccination coverage and (2) equal...
8.
Choi W, Nowalk M, Moehling Geffel K, Susick M, Saul S, Lin C, et al.
Hum Vaccin Immunother
. 2024 Oct;
20(1):2404752.
PMID: 39400298
Cigarette smoking confers additional risk from influenza. This study assessed the effect of smoking on humoral immune response to influenza vaccine. Adults ≥50 y of age were enrolled during the...
9.
Sumner K, Yadav R, Noble E, Sandford R, Joshi D, Tartof S, et al.
J Infect Dis
. 2024 Jul;
230(1):45-54.
PMID: 39052724
Background: We assessed associations between binding antibody (bAb) concentration <5 days from symptom onset and testing positive for COVID-19 among patients in a test-negative study. Methods: From October 2021 to...
10.
Altawalbeh S, Wateska A, Nowalk M, Lin C, Harrison L, Schaffner W, et al.
Vaccine
. 2024 Jul;
42(23):126127.
PMID: 39013693
No abstract available.